Optinose (OPTN) PT Lowered to $28 at BMO Capital; Sell-Off 'Very Overdone'
Tweet Send to a Friend
BMO Capital analyst Gary Nachman lowered the price target on Optinose (NASDAQ: OPTN) to $28.00 (from $30.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
